Stock Price & Analysis

Based on the analysis of Pfizer's strong dividend yield, consistent dividend growth, and stable financial performance, it is recommended to hold PFE stock. The attractive 6.58% dividend yield and 15-year dividend growth streak make it a solid choice for income-focused investors, despite current market uncertainties.

Pfizer (PFE) stock is predicted to reach a price target of $29 in 2025. This forecast is supported by analyst consensus, with Guggenheim maintaining a Strong Buy rating and a $33 price target, while UBS holds a Neutral rating with a $28 target. The stock's current price of $26.16, combined with its attractive 6.6% dividend yield and consistent dividend growth, positions it as a stable investment with moderate upside potential.

The S1 support level for PFE Stock is $24.77 ,The R1 resistant level for PFE Stock is $26.3.

As of the end of day on 2025-04-01, the price of PFE Stock was $24.62.

The target price for PFE Stock according to analyst rating is 30.64, with the highest price target at 36.00 and the lowest at 27.00. Analysts have a Moderate Buy rating on PFE Stock overall.

The market cap of PFE is $139.2B.

Pfizer (PFE) appears undervalued based on its low forward P/E ratio of 8.8, which is significantly below the industry average of 18.7. The stock offers a high dividend yield of 6.37%, appealing to income investors. Pfizer's Q4 revenue of $17.76 billion exceeded expectations, and the company expects solid growth in the second half of the decade. Analysts have mixed ratings, but many see upside potential. Overall, Pfizer's valuation metrics and growth prospects suggest it is not overvalued.

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

Price Prediction for PFE Stock in 2030

Based on current trends and analysis, Pfizer's stock price could reach $45 by 2030, driven by its strong pipeline, dividend yield, and strategic acquisitions. The company's focus on innovation and cost savings supports long-term growth.

PFE has a total of 88000 employees.